Advanced Biomed Inc. (ADVB) Key Metrics
ADVB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $6.6M
- Enterprise value
- $7.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 51.5
- Price / book
- 1.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
ADVB key metrics, FY2021–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsADVB valuation Price multiples at each fiscal year-end price.
ADVB returns How much profit the business earns on the capital it uses.
ADVB per-share figures Results divided by the shares outstanding at year-end.
ADVB financial health Debt, liquidity and how easily interest is covered.
ADVB valuation history
ADVB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ADVB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ADVB price vs earnings per share
ADVB key metrics
FY2021–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $5.8M | $15.1M | — | — | — | — |
| Enterprise value | $5.5M | $13.5M | — | — | — | — |
| P/E ratio | 0.9 | — | — | — | — | — |
| Price / book | 0.5 | 4.4 | — | — | — | — |
| Earnings yield | 114.6% | −0.7% | — | — | — | — |
| Free cash flow yield | −16.5% | −1.2% | — | — | — | — |
| Share price at fiscal year-end | $4.65 | $14.00 | — | — | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | $5.33 | −$0.09 | −$2.57 | −$0.11 | −$3.72 | −$1.70 |
| Operating cash flow per share | −$0.05 | −$0.17 | −$1.97 | −$2.74 | −$0.69 | −$0.44 |
| Free cash flow per share | −$0.77 | −$0.17 | −$2.03 | −$2.94 | −$1.90 | −$0.46 |
| Cash per share | $0.31 | $2.68 | $2.41 | $2.42 | $4.42 | $0.06 |
| Book value per share | $9.80 | $3.21 | $1.54 | $1.21 | $3.23 | $0.90 |
| Tangible book value per share | $9.80 | $3.21 | $1.43 | $0.98 | $2.85 | $0.90 |
| Capex per share | $0.00 | $0.00 | $0.07 | $0.20 | $1.21 | $0.02 |
| Debt per share | $0.03 | $1.17 | $0.12 | $0.22 | $0.44 | $0.01 |
| Shares outstanding | 1.3M | 1.1M | 1.1M | 1.1M | 1.1M | 1.1M |
| Change in shares outstanding | +15.8% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | 84.8% | −3.9% | −187.4% | −5.1% | −180.3% | −188.2% |
| Return on invested capital (ROIC) | −2.3% | −14.5% | — | — | — | −158.2% |
| Return on assets (ROA) | 65.9% | −1.9% | −61.4% | −2.1% | −104.3% | −182.6% |
| Return on tangible assets | 48.6% | −1.6% | −64.1% | −2.8% | −63.9% | −182.6% |
| Income quality (OCF / net income) | −0.01 | — | — | — | — | — |
| Financial health | ||||||
| Total debt | $33,845 | $1.3M | $128,657 | $242,326 | $476,827 | $7,209 |
| Cash & short-term investments | $385,535 | $2.9M | $2.6M | $2.6M | $4.8M | $65,922 |
| Net debt | −$351,690 | −$1.6M | −$2.5M | −$2.4M | −$4.3M | −$58,713 |
| Debt / equity | 0.00 | 0.36 | 0.08 | 0.19 | 0.14 | 0.01 |
| Debt / assets | 0.00 | 0.19 | 0.03 | 0.05 | 0.07 | 0.01 |
| Net debt / EBITDA | — | — | — | −8.97 | — | — |
| Current ratio | 9.33 | 2.09 | 1.12 | 0.85 | 1.67 | 32.22 |
| Quick ratio | 9.33 | 2.09 | 1.12 | 0.85 | 1.67 | 32.22 |
| Interest coverage | -888.7 | — | — | — | — | — |
| Working capital | $12.3M | $3.1M | $318,650 | −$489,595 | $2.0M | $885,147 |
| Invested capital | $11.9M | $1.8M | −$816,058 | −$1.1M | −$815,441 | $917,529 |
| Tangible asset value | $12.3M | $3.5M | $1.5M | $1.1M | $3.1M | $976,242 |
| Net current asset value | $12.3M | $3.0M | $254,121 | −$508,401 | $1.8M | $883,366 |
| Graham number | $34.28 | — | — | — | — | — |
| Graham net-net per share | −$0.62 | −$0.12 | −$0.17 | −$0.62 | $1.56 | $0.03 |
| Capital allocation | ||||||
| Capex / revenue | 0.1% | — | — | — | — | — |
| Capex / depreciation | — | 0.09 | 0.19 | 0.58 | 10.36 | 0.44 |
| Stock-based compensation / revenue | 42,169.5% | — | — | — | — | — |
| SG&A / revenue | 112,528.5% | — | — | — | — | — |
| Efficiency | ||||||
| Days sales outstanding | 18,968.9 | — | — | — | — | — |
| Days of inventory on hand | — | — | -183.9 | — | — | — |
| Days payables outstanding | — | 10,941.0 | 18,225.2 | 21,412.2 | 31,078.2 | 34.9 |
| Receivables turnover | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | — | 0.03 | 0.02 | 0.02 | 0.01 | 10.47 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $213,699 | $7,140 | $5,569 | $83,666 | $81,468 | $419 |
| Average payables | — | $321,067 | $626,648 | $697,511 | $381,198 | $194 |
| Average inventory | — | — | −$6,324 | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 2.7% | 5.4% | 6.1% | 0.0% |
Computed from ADVB's annual financial statements (latest annual report filed October 13, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ADVB valuation and financial ratios
At the end of fiscal 2026 (June 30, 2026), Advanced Biomed traded at 0.9 times earnings. Advanced Biomed earned a return on equity of 84.8% and a return on invested capital of −2.3% in fiscal 2026. It ended the year with $0.0 million of debt and $0.4 million in cash and short-term investments, a net cash position of $0.4 million. The share count rose 15.8% from 1.1M to 1.3M over 5 years.
See the ADVB income statement, the ADVB chart for price history, or the ADVB stock overview for the latest quote and news.
ADVB key metrics FAQ
What is Advanced Biomed's P/E ratio?
Advanced Biomed traded at 0.9 times earnings at the end of fiscal 2026.
What is Advanced Biomed's return on equity?
Advanced Biomed's return on equity (ROE) was 84.8% in fiscal 2026: net income of $6.7 million on average shareholders' equity of $7.9 million.
What is Advanced Biomed's ROIC?
Advanced Biomed's return on invested capital was −2.3% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Advanced Biomed have?
Advanced Biomed had total debt of $0.0 million at the end of fiscal 2026, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Advanced Biomed's free cash flow yield?
Advanced Biomed generated -$1.0 million of free cash flow in fiscal 2026, a free cash flow yield of −16.5% on its market value at year-end ($5.8 million).
What is Advanced Biomed's current ratio?
Advanced Biomed's current ratio was 9.33 at the end of fiscal 2026: current assets were 9.33 times current liabilities.